NEW YORK, N.Y. – July 31, 2026 - Supira Medical recently highlighted a major clinical milestone on LinkedIn, welcoming Columbia University Irving Medical Center as a trial partner following their successful enrollment of a highly complex subject in the SUPPORT II pivotal study.
ST. CLOUD, Minn. – June 23, 2026 - CentraCare Heart & Vascular recently shared a major clinical milestone on LinkedIn, announcing their program as the first in the Midwest to successfully enroll a patient in the SUPPORT II clinical trial evaluating the investigational Supira System.
LOS GATOS, Calif., April 8, 2026 – Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II Pivotal Trial. The trial is designed to support a future PMA submission and represents a critical step toward U.S. market entry.
LOS GATOS, CA., March 26, 2025 – Supira Medical, Inc. (Supira), a clinical-stage Shifamed portfolio company, today announced the successful completion of an oversubscribed Series E financing round, raising $120M to accelerate the company’s mission of transforming the percutaneous ventricular assist device (pVAD) market.
LOS GATOS, Calif., Nov. 21, 2024 – Supira Medical, Inc. (Supira), a Shifamed portfolio company, announced today the initiation and successful patient enrollment in the company’s U.S. EFS. This multi-center prospective, single arm clinical study will evaluate the safety and feasibility of Supira’s innovative low-profile, high-flow percutaneous ventricular assist device (pVAD) in patients undergoing high-risk percutaneous coronary intervention (HRPCI).
Los Gatos, Calif., November 21, 2023 - Supira Medical, Inc., a Shifamed portfolio company, announced today that it has received U.S. Food and Drug Administration (FDA) breakthrough device designation for its Supira System, a next-generation percutaneous ventricular assist device (pVAD). This approval comes as the company closed $40M in Series D financing and prepares to initiate its U.S. clinical program.
Los Gatos, Calif., October 20, 2023 - Supira Medical, Inc., a Shifamed portfolio company, announced today that the company’s percutaneous ventricular assist device (pVAD) will be showcased in multiple sessions, including a live case presentation, during the 2023 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place October 23-26 in San Francisco, CA.
Los Gatos, Calif., May 12, 2023 – Supira Medical, Inc., a Shifamed portfolio company, announced today that its next generation percutaneous ventricular assist device (pVAD) was selected following a highly competitive review process to be highlighted as part of this year’s European Association of Percutaneous Cardiovascular Interventions conference (EuroPCR) Innovator’s Day in Paris, France. Gagan Singh M.D., M.S., Director of Clinical Cardiovascular Research at University of California, Davis, will present on behalf of the company during the “Innovations in Heart Failure: Pumps, Remodeling and Monitoring” session beginning at 12:05 pm CET on Monday, May 15th in the Theatre Havane of the Palais de Congrès. Additionally, Supira Medical will be at booth M23 where PCR attendees can learn more about the system.
Los Gatos, Calif., September 16, 2022 – Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal investigator, Adrian Ebner, M.D., Head of the Cardiovascular Department at the Italian Hospital Asuncion Paraguay. The prospective, single-arm, single-center study will evaluate the safety and performance of Supira’s low-profile, high-flow percutaneous ventricular assist device (pVAD) to support cardiovascular hemodynamics in patients undergoing high-risk percutaneous coronary interventions (HRPCI).
Los Gatos, Calif., February 28, 2022 – Supira Medical, Inc., a Shifamed portfolio company that is focused on developing a next-generation solution for temporary mechanical circulatory support, announced today the closing of $30M in Series C financing. Led by Cormorant Asset Management and The Capital Partnership (TCP), with participation from 415 CAPITAL, AMED Ventures, PA MedTech VC Fund and Shifamed angel investors, the funds will be used to finalize product development and initiate a first-in-human clinical study for the company’s high-flow, low-profile percutaneous ventricular assist device (pVAD).
